Jonghyun Bae1,2,3, Jin Zhang3, Mihaela Stavarache3, Ayesha Das3, Sawwal Qayyum3, Karl Kiser3, and Sungheon Gene Kim3
1Vilcek Institute of Biomedical Science, New York University School of Medicine, New York, NY, United States, 2Radiology, Center for Advanced Imaging Innovation and Research, New York, NY, United States, 3Radiology, Weill Cornell Medical College, New York, NY, United States
Synopsis
This study explores two different approachs
of measuring subtle BBB disruption. To induce different levels of BBB
disruption, we used a focused ultrasound (FUS) sonication with intravenously
injected microbubbles with an animal model. Each animal underwent FUS procedure
with different acoustic power levels. We compared the changes measured using DCE-MRI
with Gadolinium-based contrast agent for volume transfer rate constant and Ferumoxytol-based
ACE-MRI to measure transendotheliel water exchange rate. Our results suggest
that both the water exchange rate and the contrast exchange rate show sensitive
detection of subtle BBB disruption, which could shed light on understanding different
permeability changes in BBB.
Purpose
Dynamic contrast enhanced (DCE)-MRI has been widely used as a
quantitative tool for assessing the subtle blood-brain barrier (BBB)
disruption, suggested as a potential biomarker for early Alzheimer’s disease [1]. However, due to this subtle disruption, the
extravasation of Gadolinium contrast agent is expected to be also small, which
in turn requires a relatively long scan time to observe [2]. Ferumoxytol has recently gained attention as
an alternative contrast agent for MR imaging [3, 4]. Due to its large molecular size, Ferumoxytol
molecules remain in blood vessels with subtle BBB disruption. Utilizing its
paramagnetic characteristics of T1-shortening effect on nearby
water, we aim to measure the water exchange rate between the intravascular and
extravascular space. We compare the contrast agent exchange rate and the water
exchange rate for the assessment of different levels of BBB disruption induced
by Focused Ultrasound (FUS).Method
Focused Ultrasound:
The Sprague Dawley Rats (Female, n=5, 6-8
weeks old, body weight= 250-350g) underwent Stereotactic Focused Ultrasound
procedures with different acoustic power. The animals were injected with
Optison microbubbles via a tail vein catheter while transmitting the ultrasound
wave. This procedure is known to temporarily induce BBB disruption by
sonicating the microbubbles in the vessels [5]. Each rat received different
acoustic power levels ranging from 0.2 to 1.0MPa with an increment of 0.2MPa,
prior to MRI scan as shown in Figure 1.
DCE-MRI with Gadolinium-based contrast
agent:
A 3D golden-angle radial sampling sequence
with ultrashort echo time was employed to acquire dynamic scans. The Gadolinium-based
contrast agent (gadobutrol, 0.1mMol/kg) was injected at 2min into the scan via
tail-vein catheter. The total scan time for DCE-MRI was 28min. The imaging
parameters are TE/TR = 0.028 / 10ms, flip-angle = 10°, spatial resolution = 0.203x0.203x0.203mm3, the image matrix = 128x128x128. The acquired image was reconstructed
with iterative GRASP reconstruction with the temporal resolution of 5s [6]. Prior to DCE-MRI scan,
similar 3D radial sequence was employed to acquire pre-contrast T1 maps using 3
different flip-angles.
ACE-MRI with Ferumoxytol-based contrast
agent:
The DCE-MRI scan with Ferumoxytol
injection was conducted using the Active Contrast Encoding MRI (ACE-MRI)
sequence that uses multiple flip angles to encode the effect of water
exchange effect on the dynamic signal intensity time curve. ACE-MRI was
conducted with the 3D radial sequence with ultrashort echo time (TE = 0.028 ms)
with a series of 14 segments with different flip
angles in the order of [10°-10°-10°-10°-2°-10°-20°-10°-5°-10°-15°-10°-25°-10°]. The diluted Ferumoxytol
(0.4 – 1.6mg Fe / kg) was injected at 1min into the scan and the scan continued
for another 9min. The images were reconstructed with 2.5s temporal resolution.
Data Analysis:
For DCE-MRI data with gadobutrol, the
pharmacokinetic model analysis was performed using the graphical Patlak model [7]. The arterial
input-function (AIF) was sampled from the image by selecting the top 0.5%
enhancing voxels. The permeability-surface area product (PS) was
obtained to assess the exchange rate for Gadolinium contrast agent.
For ACE-MRI data with ferumoxytol, the
extended Tofts model [8] was used for modeling
the vascular and extravascular compartment. Since ferumoxytol molecules are
expected to remain in the vascular compartment, the contrast exchange rate (PS)
was assumed to be negligible (i.e., PS=0). Then the signal rising from
the water exchange between the intravascular and extravascular compartment was
modelled as similar to the previous study [6], with the absence of
transcytolemmal water exchange. The sonicated region was identified using the PS
map from Gd and selected as ROI for fitting the model. The mean residence time
of water denoted as τb in
the ROI was estimated for assessing the water exchange rate at the sonicated
region.Results
Figure 2 shows an example fit of each
model for DCE and ACE-MRI in the ROI-averaged signal. As shown, each model was
able to describe the dynamics of both contrast agents. In Figure 3, the PS
map obtained from the DCE-MRI data are displayed for different acoustic power.
With the increase of acoustic power, the increased PS levels were observed.
Figure 4 shows the box-whisker plot of
both PS and τb in
the sonicated ROI. The median value of τb shows the decrease in the mean water residence
time with the increased level of BBB disruption. In Figure 5, the exchange rates
for both Gadolinium and the water (PSw = 1/τb) are
compared. As shown in the plot, both exchange rates are increased with the
higher acoustic power, while the PSw appears to show more
monotonical increase with the acoustic power.Discussion & Conclusion
The preliminary results of the study
suggest that both PS and PSw are sensitive
to subtle changes of BBB induced by FUS. Note that the level of PS in the
sonicated area is higher than that of the normal brain, but substantially lower
than that of tumor (in about 3 orders of magnitude). PS and PSw
measures BBB permeability using Gd and water molecules that are noticeably
different in their size. Hence, we expect that using these two measures jointly
would provide a better picture of BBB changes occurring in various
neurodegenerative diseases. The synergistic role of these two measures will be
further investigated in future studies.Acknowledgements
NIH R01CA160620 References
1. Montagne,
A., et al., Blood-brain barrier breakdown
in the aging human hippocampus. Neuron, 2015. 85(2): p. 296-302.
2. Heye,
A.K., et al., Assessment of blood–brain
barrier disruption using dynamic contrast-enhanced MRI. A systematic review.
NeuroImage: Clinical, 2014. 6: p.
262-274.
3. Bashir,
M.R., et al., Emerging applications for
ferumoxytol as a contrast agent in MRI. Journal of Magnetic Resonance
Imaging, 2015. 41(4): p. 884-898.
4. Hamilton,
B.E., et al., Ferumoxytol-enhanced MRI is
not inferior to gadolinium-enhanced MRI in detecting intracranial metastatic
disease and metastasis size. American Journal of Roentgenology, 2020. 215(6): p. 1436-1442.
5. Vlachos,
F., Y.S. Tung, and E. Konofagou, Permeability
dependence study of the focused ultrasound‐induced blood–brain barrier opening
at distinct pressures and microbubble diameters using DCE‐MRI. Magnetic
resonance in medicine, 2011. 66(3):
p. 821-830.
6. Zhang,
J. and S.G. Kim, Estimation of
cellular‐interstitial water exchange in dynamic contrast enhanced MRI using two
flip angles. NMR in Biomedicine, 2019. 32(11):
p. e4135.
7. Patlak,
C.S., R.G. Blasberg, and J.D. Fenstermacher, Graphical evaluation of blood-to-brain transfer constants from
multiple-time uptake data. Journal of Cerebral Blood Flow & Metabolism,
1983. 3(1): p. 1-7.
8. Tofts, P.S., et al., Estimating kinetic parameters from dynamic
contrast‐enhanced T1‐weighted MRI of a diffusable tracer: standardized
quantities and symbols. Journal of Magnetic Resonance Imaging: An Official
Journal of the International Society for Magnetic Resonance in Medicine, 1999. 10(3): p. 223-232.